SmallCapReview.com has been a leading site for information on small cap stocks, penny stocks and microcaps since 1999, to receive the free SmallCapReview newsletter and be entered to win a Free iPod Touch visit http://www.smallcapreview.com.
Grifols (GRF.MC) a global healthcare company and leading producer of plasma protein therapies, and Talecris (Nasdaq: TLCR) trading at $19.93, Up $4.02, a U.S.-based biotherapeutics products company, today announced that they have signed a definitive agreement through which Grifols will acquire Talecris for a combination of cash and newly-issued Grifols non-voting shares having an aggregate value today of approximately $3.4 billion (euro 2.8 billion), creating a global leader of life-saving and life enhancing plasma protein therapeutics.
The combination of Grifols and Talecris will
create a vertically integrated and diversified international plasma protein
therapies company, bringing together complementary geographic footprints and
products, as well as increased manufacturing scale. Grifols' leading global
footprint will benefit from Talecris' strong presence in the
United States and Canada. Grifols'
available manufacturing capacity will enable Talecris to increase production in
the near term. As a result, the combined company will be better able to
meet the needs of more patients with under-diagnosed disease states around the
world.
What They Do: Talecris Biotherapeutics is a global biotherapeutic and
biotechnology company that discovers, develops and produces critical care
treatments for people with life-threatening disorders in a variety of
therapeutic areas including immunology, pulmonology, neurology, critical care,
and hemostasis.
Fronteer Gold (AMEX: FRG) trading at $6.52, Up $0.69. Today announced reports new high-grade drill results from Silica Ridge, one of four gold deposits that comprise our Sandman project, and announces approval of an expanded Plan of Operations for the Nevada property.
Newmont USA Limited, as project operator, completed a 19-hole drill program at Silica Ridge in April. Results received from the first five holes show continued intersection of high-grade oxide gold mineralization.
What They Do: Fronteer Development Group Inc. engages in the acquisition,
exploration, and development of mineral resource properties in Canada, the
United States, Mexico, and Turkey.
Bristol Myers Squibb (NYSE: BMY) trading at $23.94, Up $1.50. Announced Saturday, along with Otsuka Pharmaceutical Co., Ltd. that Phase III study results in which Sprycel (dasatinib) 100 mg once daily demonstrated a superior rate of confirmed complete cytogenetic response(CCyR) compared to Gleevec (imatinib mesylate). This study, known as DASISION, compared the investigational use of SPRYCEL versus Gleevec as a first-line treatment for patients with chronic phase chronic myeloid leukemia (CML-CP).
The data were published today in the New England Journal of Medicine and presented at the 46th Annual Meeting of the American Society of Clinical Oncology.
What They Do: Bristol-Myers Squibb and Otsuka Pharmaceutical Co., Ltd. are collaborative partners in the commercialization of SPRYCEL in the United States, Japan and major European countries.
About SmallCapReview
Copyright SmallCapReview. SmallCapReview.com is a leading site for news on small-caps, penny stocks and microcaps. SmallCapReview has built a loyal opt-in following for their investor products by providing a newsletter at no cost, sent to subscribers, highlighting select stocks in play, to register visit
http://www.smallcapreview.com. To follow us on Twitter visit
http://twitter.com/SmallCapReview.
